Nuclear Medicine Imaging of Prostate Cancer

Dear Colleagues,

Molecular imaging of prostate cancer is currently a rapidly evolving area, combining new technologies such as positron emission tomography and magnetic resonance (PET/MR) imaging, with new developments of radionuclides, targeting various aspects of prostate cancer.

In the last few years, a new class of small molecules targeting the prostate specific membrane antigen (PSMA-tracers) became available. Since then, the use of ⁶⁸Ga- or ¹⁸F-labelled PSMA PET/CT or PET/MR has rapidly increased, due to an excellent contrast-to-noise ratio and high image resolution, thereby improving the detectability of small lesions. For the detection of biochemical recurrence of prostate cancer, PSMA PET soon became an integral part of patient care. Further applications are under investigation, such as staging, biopsy guidance, and therapy response assessment. However, PSMA is not expressed on every prostate cancer. Therefore, further investigation of alternative targets is still needed not only within nuclear medicine but also in molecular pathology to find optimal targets and imaging approaches for every patient.

In this upcoming issue, we intend to focus on prostate imaging using both PSMA or alternative targets (e.g., GRP-receptor, amino acid transport) for the detection or therapy of prostate cancer. Both original research and review articles are welcomed.

Please feel free to contact us and send us your suggestions that you would like to discuss beforehand. We look forward to and welcome your participation in this Special Issue.

Dr. Irene A. Burger
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.